South Africa regulator recommends lifting J&J vaccine pause after some conditions By Reuters

2/2
© Reuters. COVID-19 vaccination at Khayelitsha Hospital near Cape Town

2/2

(Reuters) – South Africa’s health regulator, on Saturday, recommended that the government lift the pause on administering drugmaker Johnson & Johnson (NYSE:)’s COVID-19 vaccines, given that certain conditions are met.

“These conditions include, but are not limited to, strengthened screening and monitoring of participants who are at high risk of a blood clotting disorder,” the South African Health Products Regulatory Authority (SAHPRA) said.

“In addition, measures are to be implemented to ensure the safe management of any participants who develop vaccine-induced thrombosis and thrombocytopenia (VITT),” the statement added.

SAHPRA said on Wednesday that it had recently reviewed data from Johnson & Johnson’s local research study immunising healthcare workers and found no major safety concerns.

South Africa suspended the rollout of the J&J vaccine in the “implementation study” on Tuesday, after U.S. health agencies recommended pausing its use because of rare cases of blood clots in six people inoculated with it, out of some 7 million people who have received the shot in the United States.

A U.S. panel will meet again next week to discuss whether the pause on the use of the vaccine should continue, after delaying a vote on the matter earlier this week.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


*